Product Description
Levomilnacipran is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD). (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Levomilnacipran-(Fetzima))
Mechanisms of Action: Serotonin/Noradrenaline Reuptake Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Brazil | Canada | Chile | Egypt | France | Hong Kong | India | Mexico | Taiwan | Thailand | Turkey | United Kingdom | United States | Vietnam
Approved Indications: Fibromyalgia | Myalgia | Depressive Disorder | Depressive Disorder, Major | Fibromyalgia | Myalgia
Known Adverse Events: Hypertension | Dizziness | Headache | Hyperhidrosis | Constipation | Erectile Dysfunction
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|